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Abstract
Introduction: Chlamydophila pneumoniae is a respiratory pathogen known to infect the upper and lower
respiratory tracts. Infection severity can range from sub-clinical pulmonary infection to acute respiratory distress
syndrome.
Case presentation: A previously healthy 62-year-old Caucasian man was admitted to our hospital for acute
respiratory failure. Serum samples obtained every week starting from the day of admission showed clear-cut
seroconversion for C. pneumoniae antibodies. All other cultures obtained during the first days of hospitalization
were negative. Despite maximal ventilatory support (high positive end expiratory pressure, fraction of inspired
oxygen of 1.0, nitric oxide inhalation, neuromuscular blocking agents and prone positioning), our patient remained
severely hypoxemic, which led us to initiate an extracorporeal membrane oxygenation treatment. Extracorporeal
membrane oxygenation and hemodiafiltration were withdrawn on day 12. Our patient was extubated on day 18
and discharged from our Intensive Care Unit on day 20. He went home a month later.
Conclusion: We describe the first published case of acute respiratory distress syndrome due to C. pneumoniae
infection successfully treated by extracorporeal membrane oxygenation, a very useful tool in this syndrome. A
quick and specific method for the definite diagnosis of Chlamydophila infection should be developed.
Introduction
Chlamydophila pneumoniae is an obligate intracellular
Gram-negative bacterium. The spectrum of disease, in
addition to pneumonia and influenza-like illness,
includes pharyngitis, sinusitis, bronchitis, exacerbation
of chronic obstructive pulmonary diseases and reactive
arthritis [1-5]. C. pneumoniae accounts for 6% to 20% of
cases of community-acquired pneumonia (CAP) [1,2].
Many of these cases have few symptoms and don’t
require hospitalization (’walking pneumonia’). However,
more severe cases may occur, with up to 18% requiring
hospitalization [6] and even mechanical ventilation,
especially in elderly, immunocompromised hosts and
patients with coexisting cardiopulmonary disease [7],
but also, rarely, in previously healthy adults [8].
Old and new macrolides are effective against C. pneu-
moniae and have been recommended as first-line treat-
ment. New fluoroquinolones are also effective in vitro
against C. pneumoniae and can be used. Studies have
shown that 35% to 47% of C. pneumoniae pneumonia is
mixed with other pathogens, the most common being
Streptococcus pneumoniae [9,10].
We describe the case of severe CAP due to C. pneu-
moniae infection in a previously healthy adult patient,
with acute respiratory distress syndrome (ARDS) neces-
sitating extracorporeal membrane oxygenation (ECMO).
Case presentation
A previously healthy 62-year-old Caucasian man was
admitted to our hospital for acute respiratory failure.
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earlier and a non-productive cough three days later. He
had not received any antimicrobial treatment prior to
his hospitalization, the diagnosis of his primary care
physician being influenza (A/H1N1v), given the ongoing
outbreak.
His medical history was remarkable for possible viral
pericarditis without any consequence in 2007 and a gas-
tric ulcer 30 years earlier. He had no drinking habits.
He did not smoke cigarettes. He had not travelled
abroad recently. He did not have any bird or pet.
On hospital admission, our patient was in acute
respiratory distress. His respiratory rate was 40 breaths/
minute, his temperature 38.3°C, his pulse 98 beats/min-
ute and his blood pressure 114/60 mmHg. Auscultation
revealed crackles over his whole left lung and over his
right lower lung field. A computed tomography scan
showed diffuse alveolar type infiltrates in his two lung
fields with air bronchograms (Figure 1).
Arterial blood gas analysis (under 100% oxygen
through a non-rebreathing mask) showed pH 7.54, a
partial pressure of carbon dioxide (PaCO2) 44 mmHg,
partial pressure of oxygen (PaO2)3 8m m H ga n da n
arterial blood oxygen saturation of 84%. His white blood
cell count was 5780 cells/μL (86% neutrophils) and the
erythrocyte sedimentation rate was 92 mm/h.
Laboratory values showed serum creatinine at 1.7 mg/
dL, potassium at 2.8 mEq/L, creatine phosphokinase at
644 IU/L, liver test alterations (alanine transaminase at
87 IU/L), lactate dehydrogenase elevation (1708 IU/L)
and D-Dimers at 7420 ng/mL, activated partial throm-
boplastin time of 72 seconds, normal international nor-
malized ratio and blood platelets at 166.000/μL. His
urine output was 0.4 mL/kg/h over six hours. An elec-
trocardiogram showed a sinus tachycardia with a com-
plete right bundle branch block.
Serum samples obtained every week as from the day
of admission showed a clear-cut seroconversion for C.
pneumoniae antibodies (the course of the antibody titers
shown in Table 1).
Paired serum samples and antigens against the most
common microorganisms, including atypical bacteria
and common viruses such as A/H1N1v, were negative.
Blood, sputum and urine tests for bacterial cultures
obtained during the first day of hospitalization were
negative.
Our patient was treated by amoxycillin-clavulanic acid,
moxifloxacin and oseltamivir. His respiratory status
necessitated endotracheal intubation and mechanical
ventilation. Severe arterial hypotension prompted nore-
pinephrine infusion and the insertion of a pulmonary
artery catheter. The initial hemodynamic pattern was
Figure 1 Unenhanced computed tomography scan through the thorax showing alveolar type infiltrates of the two lung field with air
bronchograms.
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Table 2). Metabolic data showed a mixed venous satura-
tion of 56%.
Despite maximal ventilatory support (high positive end
expiratory pressure, an inspired oxygen fraction (FiO2)
of 1.0, nitric oxide inhalation of 20 ppm, neuromuscular
blocking agents and prone positioning), our patient
remained severely hypoxemic (PaO2/FiO2 =3 8 )w h i c h
led us to initiate ECMO treatment.
Venovenous ECMO (a Sorin Revolution centrifugal
pump, a Sorin ECCO oxygenator and a Sorin Satcrit
console from Sorin Group, Milano, Italy) was put in
place on the fifth day of hospitalization, with a left
femoral 22-Fr drainage cannula and a right femoral 23-
Fr return cannula, inducing a drastic improvement of
our patient’s oxygenation parameters (PaO2 = 120
mmHg). The mixed venous oxygen saturation (SVO2)
increased from 56% to 86%. Continuous veno-venous
hemodiafiltration (CVVHDF) renal replacement therapy
was also initiated on day three because of acute renal
failure.
There were no severe complications of the ECMO
treatment except for hemorrhagic suffusion of the two
femoral catheter insertion points, requiring a blood
transfusion.
ECMO and CVVHDF were withdrawn on day 12. Our
patient was extubated on day 18 and discharged from
our Intensive Care Unit on day 20. He went home a
month later. He is now in good physical condition and
has returned to work and to a normal social life.
Discussion
This case illustrates the polymorphism in the presenta-
tion of C. pneumoniae infection, which can cause severe
CAP complicated by ARDS, even in immunocompetent
patients. Pneumonia and bronchitis are the most com-
mon clinical infections associated with C. pneumoniae.
The classical pulmonary presentation is a single subseg-
mental infiltrate, even though lobar consolidation or
bilateral infiltrates can also be seen.
Two major aspects are discussed below: the rationale
for the use of ECMO in ARDS patients as well as its dif-
ferent techniques, and the difficulties of diagnosing C.
pneumoniae pneumonia.
ECMO and CO2 removal
There are two main ECMO techniques according to
the type of vascular access that is used: venovenous
and venoarterial. Each one has a specific indication.
Venoarterial ECMO gives cardiac and respiratory
support. Indications for venoarterial ECMO include
postcardiac surgery (heart surgery or heart trans-
plantation), cardiogenic shock due to acute myocar-
dial infarction or acute myocarditis and intoxication.
For cardiac support, the goal is to optimize organ
perfusion (by obtaining a SVO2 greater than 70%,
which usually needs an output index of about 3 L/
min/m
2). This is achieved by choosing the appropri-
ate sizes of cannula according to the patient’sb o d y
surface area.
In isolated respiratory failure, a venovenous access is
preferred. The objective is CO2 removal at least equal to
the patient’s metabolism (roughly 3 cm
3/kg/min in
adults). The purpose of venovenous ECMO use in
ARDS patients is lung protection (reducing ventilator-
induced lung injury) through a decrease in alveolar dis-
tention permitted by the reduction in ventilator
conditions.
Even though a lot of progress has been done in tech-
nical issues, the risk-benefit ratio must be taken into
account when ECMO is proposed to a patient with
severe respiratory failure. As in all extracorporeal
devices, anticoagulation is mandatory. Many patients
will experience bleeding, which can be very severe. Con-
traindication for anticoagulation remains the most
important limitation of this technique. Previous severe
disability or poor prognosis due to underlying disease
constitutes the other main contraindication for ECMO
initiation. The main complications are bleeding, throm-
boembolism, cannula-related complications, pulmonary
embolism or infarction, aortic thrombosis and coronary
Table 1 Comparison of antibody kinetics using different
techniques
Test (units) Day one Day 13 Day 23
MIF-IgG
a (titer) 1/512 1/2048 1/4096
MIF-IgM
b(titer) < 1/10 < 1/10 < 1/10
MOMP-IgG
c (AU/mL) 102 478 > 500
LPS-IgG
d (index) 1.5 6.8 9.4
LPS-IgA
e (index) < 0.9 2.8 1.3
aMIF-IgG (Focus Diagnostics): + when > 1/512 or a four-fold rise in titer in
consecutive sera;
bMIF-IgM (Focus Diagnostics): < 1/16 = negative;
cMOMP-IgG
(C. pneumoniae IgG-ELISA plus medac): + when ≥ 28 AU/mL;
dLPS-IgG (C.
pneumoniae IgG- rELISA medac): + when index ≥ 1,1;
eLPS-IgA (C. pneumoniae
IgA- rELISA medac): + when index ≥ 1,5; doubtful: index 0.9-1.4.
Table 2 Hemodynamic values throughout Intensive Care
Unit stay till ECMO removal.
Parameters Day one Day five Day nine Day 12
HR 97 88 92 104
MAP 60 67 69 91
PCWP 18 12 7 6
CI (3.0-5.0) 3.9 4.2 2.7 4.6
ISVR (1200-2000) 861 1416 2414 1512
Noradrenaline (μg/kg/min) 1.1 0.6 0.2 0
Dobutamine (μg/kg/min) 15 20 5 0
HR: heart rate (beats per min); MAP: mean arterial pressure (mmHg); PCWP:
pulmonary capillary wedge pressure (cmH20); CI: cardiac index (L/min/m
2);
indexed systemic vascular resistance (Dyne.sec.m
2/cm
5).
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quent in a venoarterial montage type.
Discussion still stands in the literature as to whether
mechanical ventilation of more than seven days is or is
not a relative contraindication for ECMO because of
ventilation-induced lung injury [11].
The first randomized clinical trials failed to demon-
strate beneficial effect of ECMO for severe respiratory
failure in the 1970s and 1980s. Since then, technical
improvements for ECMO on one hand, and better treat-
ment of the ARDS (protective ventilation and others) on
the other hand, have renewed interest in ECMO [12].
The recent CESAR trial (Conventional Ventilation or
ECMO for Severer Adult Respiratory Failure [13])
demonstrated a possible beneficial effect of ECMO. Of
those patients referred for ECMO, there was 63% survi-
val rate at six months without disability, compared to
47% in those who were assigned to conventional man-
agement. This translates to one extra survivor without
disability for every six patients treated.
A recent Italian experience, in patients with ARDS
due to the influenza A/H1N1 virus, based on pre-emp-
tive patient centralization showed a 77% survival rate if
ECMO was started within seven days of initiation of
mechanical ventilation [11]. Indication for ECMO in
this study was refractory hypoxia or an oxygenation
index below 30 despite a PaO2/FiO2 ratio greater than
100 mmHg.
Treatment of critically ill patients affected by the 2009
Influenza A (H1N1v) outbreak in Australia and New
Zealand [14] included ECMO, with a 71% survival rate
at Intensive Care Unit discharge, an excellent result.
These three studies emphasize the renewed place of
ECMO in the treatment of severe ARDS with very good
survival rates, considering the severity of the initial
insult.
The limitation of plateau airway pressures and the low
tidal volume used in ARDS patients have been at the
cost of an increased PaCO2. There has therefore been
an increase in interest for extracorporeal CO2 removal
techniques. Different techniques have been developed
but most of them have not gone to relevant, sufficiently
powered clinical trials due to technical problems or
insufficient CO2 removal or oxygenation [15]. The
pumpless extracorporeal lung assist (PECLA), or Nova-
lung
® [Novalung GmbH, Heilbronn, Germany], is a
compact pumpless device driven by the pressure gradi-
ent between arterial and venous blood. A femoro-
femoral setting is most commonly used. The main
advantage of a pumpless device is a reduction in
mechanical blood trauma, bleeding and hemolysis. The
Novalung
® has been widely studied in ARDS. Three stu-
dies have demonstrated the clinical efficacy of this
PECLA device [16-18]. CO2 removal is efficient but
oxygenation may be insufficient in these critically ill
patients.
C. pneumoniae diagnosis
Diagnosis of C. pneumoniae pneumonia is still debated
in the current literature. According to Grayston et al.
and Saikku et al. [19,20], who first described this Chla-
mydia species, almost everybody is infected and rein-
fected with C. pneumoniae throughout his or her life.
Unspecific symptoms of C. pneumoniae infections make
the diagnosis even more difficult, with a possible under-
estimation of its frequency. Undetected infections may
lead to chronic disease with serious consequences, such
as atherosclerotic cardiovascular disease [21] or asthma.
Its incidence in CAP ranges from 3% to 22%, varying
according to the diagnostic method used [22]. The most
frequent routinely used diagnostic techniques are serolo-
gical, including complement fixation test, immunofluor-
escence assay, microimmunofluorescence (MIF) and
genus- and species-specific enzyme-linked immunosor-
bent assay (ELISA) systems. No currently available sero-
logic tests of a single serum specimen will provide
conclusive evidence of a current infection with C.
pneumoniae.
Since the publication of the Centre for Disease Con-
trol (CDC) 2001 recommendations for Nucleic Acid
Amplification Tests (NAATs) [23], a multitude of in-
house polymerase chain reaction (PCR) tests have been
described, though very few of them have been vali-
dated by the CDC. Results of NAATs may be unreli-
able because of cross-contamination, inappropriate
treatment of the clinical samples (leading to the loss of
the target nucleic acid) or the presence of inhibiting
substances [24]. Additionally, validation of these tests
is primarily analytical and not against clinically
obtained specimens.
Bacterial culture has traditionally been considered the
‘gold standard’ for diagnosis; however, its sensitivity,
even in excellent laboratories, seldom exceeds 90% and
is typically between 75% and 85%. The culture is techni-
cally difficult to implement and is only available in a few
laboratories worldwide [25].
Even though MIF is still actually considered as the
‘serological gold standard’ technique for the detection of
species-specific antibodies, there is a large discrepancy
between MIF testing for C. pneumonia and detection of
these organisms by culture or PCR. The MIF test is reli-
able for detection of a prior exposure to Chlamydiae by
the presence of immunoglobulin G (IgG) antibodies and
is relatively sensitive for the detection of IgM. IgM is an
unreliable marker of acute infection in adolescents and
adults since it is often not present, presumably because
of previous infection by a chlamydial species [24]. Addi-
tionally, MIF is quite a laborious and subjective
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dized and has significant laboratory-to-laboratory
variations.
In our institution, in order to get better sensitivity (for
example, after reinfections), better reproducibility,
greater objectivity and less cross-reactivity in the serol-
ogy tests for Chlamydiaceae, two-level serological testing
has been implemented for C. pneumoniae.T h ef i r s t
level test is a search by ELISA-technique for anti-major
outer membrane protein (MOMP) IgG and IgA antibo-
dies (C. pneumoniae-IgG & IgA-ELISA plus, Medac,
Hamburg, Germany) which are species-specific. This
permits us to screen patients. The disadvantage of anti-
MOMP antibodies is their late appearance in acute pri-
mary infection (three weeks for IgA, six to eight weeks
for IgG) and their considerable persistence in human
serum afterwards, independent of the bacterial eradica-
tion. In general, the prevalence of C. pneumoniae IgG
antibody reaches 50% in adults above 20 years of age,
and 80% in the elderly population (> 70 years old). The
second level test is another ELISA assay, rELISA
(Medac), for the detection of genus-specific anti-lipopo-
lysaccharide(LPS) antibodies. Chlamydiae contain, as a
common immunodominant antigen, the LPS to which
the first immune reaction is directed. These anti-LPSs
have the main advantage of rising quickly during acute
infection (five to ten days for IgA), allowing early diag-
nosis, and returning to normal a few weeks after the
infection and are thus associated to the eradication of
the bacterium [26]. The use of paired sera enables the
discrimination of current infections, reinfections and
reactivations (defined by titer increase) from chronic
persistent ones (constant LPS, IgG and IgA antibody
titers, present in 5% to 10% of the adult population) for
which no antibacterial treatment is needed. The latter is
due to the chronic presence of bacteria in the organism
in a latent phase (monocytes). Criteria for acute infec-
tions are a four-fold increase in IgA or IgG or a dou-
bling of IgA and IgG at 10 to 15 days.
Moreover, the described consecutive sera of our
patient underwent an additional retrospective exami-
n a t i o nb yaM I Fa s s a y( C h l a m y d i aM I FI g G&C h l a -
mydia MIF IgM, Focus Diagnostics, Cypress, CA,
USA). A straightforward IgG seroconversion could
also be observed (Table 1). Thanks to the detection
of IgA and of IgG antibodies to C. pneumoniae in
various combinations, serology allows a classification
of the state of infection. In our patient, reinfection
was diagnosed because MIF were positive on admis-
sion; there was a four-fold increase in anti-MOMP
IgG and, finally, an important rise and a rapid decline
in anti-LPS IgA.
Conclusion
C. pneumoniae can induce very severe ARDS. We
describe the first published case of ARDS due to C.
pneumoniae infection successfully treated by ECMO.
Definite Chlamydophila diagnosis remains a challenge
but should be sought for in severe ARDS patients with-
out evidence of other infectious cause. A quick and spe-
cific method for the definite diagnosis of Chlamydophila
infections should be developed.
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